关键词：生物仿制药；后续生物药品；专利保护；支持治疗
摘 要：Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Segmentation by Application

07.1 Cancer Treatment Drugs

07.2 Supportive Care Drugs

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis 2013

16.3 Other Prominent Vendors

17. Key Vendor Analysis

17.1 Biocon

17.1.1 Key Facts

17.1.2 Business Overview

17.1.3 Business Segmentation by Revenue 2014

17.1.4 Business Segmentation by Revenue 2013 and 2014

17.1.5 Recent Developments

17.1.6 SWOT Analysis

17.2 Celltrion

17.2.1 Key Facts

17.2.2 Business Overview

17.2.3 Product Segmentation

17.2.4 Business Strategy

17.2.5 Recent Developments

17.2.6 SWOT Analysis

17.3 Dr. Reddy's Laboratories

17.3.1 Key Facts

17.3.2 Business Overview

17.3.3 Business Segmentation by Revenue 2014

17.3.4 Business Segmentation by Revenue 2013 and 2014

17.3.5 Geographical Segmentation by Revenue 2014

17.3.6 Business Strategy

17.3.7 Recent Developments

17.3.8 SWOT Analysis

17.4 Hospira

17.4.1 Key Facts

17.4.2 Business Overview

17.4.3 Business Segmentation by Revenue 2013

17.4.4 Business Segmentation by Revenue 2012 and 2013

17.4.5 Geographical Segmentation by Revenue 2013

17.4.6 Business Strategy

17.4.7 Recent Developments

17.4.8 SWOT Analysis

17.5 Mylan

17.5.1 Key Facts

17.5.2 Business Overview

17.5.3 Business Segmentation by Revenue 2013

17.5.4 Business Segmentation by Revenue 2011-2013

17.5.5 Geographical Segmentation by Revenue 2013

17.5.6 Business Strategy

17.5.7 Recent Developments

17.5.8 SWOT Analysis

17.6 Sandoz

17.6.1 Key Facts

17.6.2 Business Overview

17.6.3 Product Segmentation

17.6.4 Business Strategy

17.6.5 Recent Developments

17.6.6 SWOT Analysis

18. Other Reports in this Series